You-Cheol Hwang

doi:10.4093/dmj.2019.0213

Articles

Page Path: HOME > Diabetes Metab J > Volume 43(6); 2019 > Article

Response Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9): You-Cheol Hwang; Diabetes & Metabolism Journal 2019;43(6):915-916.
DOI: https://doi.org/10.4093/dmj.2019.0213
Published online: December 26, 2019

2,559 Views
43 Download
1 Crossref
4 Scopus

Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.

Corresponding author: You-Cheol Hwang. Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, Korea. khmcilyong@khnmc.or.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

NOTES
REFERENCES

We deeply appreciate Professor Son's interest and constructive comments on our recently published article “Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus” which was published in Diabetes & Metabolism Journal [1].

As Professor Son pointed out, serum triglyceride levels can be affected by lifestyle factors including diet, exercise, and alcohol consumption [2]; unfortunately, however, we did not fully account for these factors in our analysis, and this might be another limitation of this study. Another issue regarding serum triglyceride levels was that the levels were significantly higher in the rosuvastatin and ezetimibe combination group than rosuvastatin monotherapy group at baseline. To partly overcome this limitation, we compared the percent reduction of serum triglyceride after the treatment. The results showed the reduction in serum triglyceride in both absolute value and percentage were greater in the rosuvastatin and ezetimibe combination group (30.6%) than rosuvastatin monotherapy group (7.2%, P=0.03).

In this study, all participants achieved the goal of low density lipoprotein cholesterol (LDL-C) <100 mg/dL except one subject in the rosuvastatin and ezetimibe combination group (93.8%). However, both regimens in our study were actually high intensity statin (rosuvastatin 20 mg daily) therapy or a therapy using comparable LDL-C reduction efficacy (rosuvastatin 5 mg and ezetimibe 10 mg daily) [3]. Therefore, we further analyzed the achievement of a more stringent goal: serum LDL-C <70 mg/dL. As a result, 80% of rosuvastatin 20 mg monotherapy group and 81% of rosuvastatin 5 mg and ezetimibe 10 mg combination therapy group achieved this goal.

Finally, as we described as a limitation of this study and as Professor Son mentioned, it would be necessary to compare the effects of these two lipid lowering regimens on glucose tolerance and insulin sensitivity with a longer period and more valid methods.

We would like to express our sincere gratitude to Professor Son again for the valuable comments.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY. Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus. Diabetes Metab J 2019;43:582-589. Article PubMed PMC PDF
2. Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol 2013;10:648-661. Article PubMed PDF
3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-2934. PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation
Ravinder Verma, Ajeet Kaushik, Rafa Almeer, Md Habibur Rahman, Mohamed M Abdel-Daim, Deepak Kaushik
International Journal of Nanomedicine.2021; Volume 16: 905. CrossRef

PubReader

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)

Diabetes Metab J. 2019;43(6):915-916. Published online December 26, 2019

DOI: https://doi.org/10.4093/dmj.2019.0213

XML Download

Related articles